Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 05:32 am
Share
Bukwang Pharmaceutical Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 43,420.1 million compared to KRW 42,868.57 million a year ago. Net income was KRW 483.01 million compared to net loss of KRW 421.4 million a year ago. Basic earnings per share from continuing operations was KRW 7 compared to basic loss per share from continuing operations of KRW 6 a year ago. Diluted earnings per share from continuing operations was KRW 7 compared to diluted loss per share from continuing operations of KRW 6 a year ago. Basic earnings per share was KRW 7 compared to basic loss per share of KRW 6 a year ago.
For the six months, sales was KRW 0.00022 million compared to negative sales of KRW 0.00095 million a year ago. Net loss was KRW 4,421.77 million compared to KRW 2,541.82 million a year ago. Basic loss per share from continuing operations was KRW 65 compared to KRW 37 a year ago. Diluted loss per share from continuing operations was KRW 65 compared to KRW 37 a year ago. Basic loss per share was KRW 65 compared to KRW 37 a year ago.
Bukwang Pharm Co Ltd is a Korea-based company principally engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through two segments. The Medicines and Quasi-drugs segment mainly produces and distributes pharmaceutical products including antidiabetic agents, anemic medicines, thyroid parathyroid hormone drugs, antihistamines, epileptic drugs, bronchodilators, stomatitis drugs, anti-malignant tumors, gum nutrition, hepatitis treatments, targeted anticancer agents, and others. The Research and Development segment mainly researches and develops pharmaceutical products.